Disruption of muscle renin-angiotensin system in AT 1a -/- mice enhances muscle function despite reducing muscle mass but compromises repair after injury

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 303, Issue 3, 2012, Pages 321-331

  Murphy, Kate T ^a   Allen, Andrew M ^a   Chee, Annabel ^a   Naim, Timur ^a   Lynch, Gordon S ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiotensin type 1 receptor; Atrophy; Regeneration; Wasting

Indexed keywords

ANGIOTENSIN 1A RECEPTOR; COLLAGEN; GAMMA INTERFERON; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; MESSENGER RNA; MYOD1 PROTEIN; MYOGENIC FACTOR 5; MYOGENIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; GENE EXPRESSION; GRIP STRENGTH; INFLAMMATION; LOCOMOTION; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE CONTRACTILITY; MUSCLE FORCE; MUSCLE FUNCTION; MUSCLE INJURY; MUSCLE MASS; MUSCLE REGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ROTAROD TEST; SKELETAL MUSCLE; TASK PERFORMANCE; TIBIALIS ANTERIOR MUSCLE;

ANIMALS; COLLAGEN TYPE II; ELAPID VENOMS; MALE; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; MUSCLE FIBERS, SKELETAL; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUSCULAR ATROPHY; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; WOUND HEALING;

EID: 84865654068     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00007.2012     Document Type: Article

References (50)

1. Azizi M, Menard J, Bissery A, Guyenne TT, Bura-Riviere A, Vaidy-anathan S, Camisasca RP. Pharmacologic demonstration of the syner-gistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 15: 3126-3133, 2004.
2. Bedair H., Karthikeyan T, Quintero A, Li Y, Huard J. Angiotensin II receptor blockade administered after injury improves muscle regeneration and decreases fibrosis in normal skeletal muscle. Am J Sports Med 36: 1548-1554, 2008.
3. Bish LT, Yarchoan M, Sleeper MM, Gazzara JA, Morine KJ, Acosta P, Barton ER, Sweeney HL. Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice. PLos One 6: e20856, 2011.
4. Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 82: 291-329, 2002.
5. Blanco CE, Sieck GC, Edgerton VR. Quantitative histochemical determination of succinic dehydrogenase activity in skeletal muscle fibres. Histochem J 20: 230-243, 1988.
6. Borghi C, Boschi S, Ambrosioni E, Melandri G, Branzi A, Magnani B. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 33: 40-45, 1993.
7. Brooks SV, Faulkner JA. Contractile properties of skeletal muscles from young, adult and aged mice. J Physiol 404: 71-82, 1988.
8. Burks TN, Andres-Mateos E, Marx R, Mejias R, Van Erp C, Simmers JL, Walston JD, Ward CW, Cohn RD. Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. Sci Transl Med 3: 82ra37, 2011.
9. Burniston JG, Saini A, Tan LB, Goldspink DF. Angiotensin II induces apoptosis in vivo in skeletal, as well as cardiac, muscle of the rat. Exp Physiol 90: 755-761, 2005.
10. Chargé SB, Rudnicki MA. Cellular and molecular regulation of muscle regeneration. Physiol Rev 84: 209-238, 2004.
11. Chen D, Bassi JK, Walther T, Thomas WG, Allen AM. Expression of angiotensin type 1A receptors in C1 neurons restores the sympathoexci-tation to angiotensin in the rostral ventrolateral medulla of angiotensin type 1A knockout mice. Hypertension 56: 143-150, 2010.
12. Cheng M, Nguyen MH, Fantuzzi G, Koh TJ. Endogenous interferon--γ is required for efficient skeletal muscle regeneration. Am J Physiol Cell Physiol 294: C1183-C1191, 2008.
13. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, Gamradt M, ap Rhys CM, Holm TM, Loeys BL, Ramirez F, Judge DP, Ward CW, Dietz HC. Angiotensin II type 1 receptor blockade attenuates TGF-fj-induced failure of muscle regeneration in multiple myopathic states. Nat Med 13: 204-210, 2007.
14. Danser AH, Koning MM, Admiraal PJ, Sassen LM, Derkx FH, Verdouw PD, Schalekamp MA. Production of angiotensins I and II at tissue sites in intact pigs. Am J Physiol Heart Circ Physiol 263: H429-H437, 1992.
15. De Luca A, Pierno S, Liantonio A, Cetrone M, Camerino C, Fraysse B, Mirabella M, Servidei S, Ruegg UT, Conte Camerino D. Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. J Pharmacol Exp Ther 304: 453-463, 2003.
16. Delp MD, Duan C. Composition and size of type I, IIA, IID/X, and IIB fibers and citrate synthase activity of rat muscle. J Appl Physiol 80: 261-270, 1996.
17. Eley HL, Russell ST, Tisdale MJ. Mechanism of attenuation of muscle protein degradation induced by tumor necrosis factor-a and angiotensin II by fj-hydroxy-fj-methylbutyrate. Am J Physiol Endocrinol Metab 295: E1417-E1426, 2008.
18. Gehrig SM, Koopman R, Naim T, Tjoakarfa C, Lynch GS. Making fast-twitch dystrophic muscles bigger protects them from contraction injury and attenuates the dystrophic pathology. Am J Pathol 176: 29-33, 2010.
19. Gehrig SM, Lynch GS. Emerging drugs for treating skeletal muscle injury and promoting muscle repair. Expert Opin Emerg Drugs 16: 163-182, 2011.
20. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 32: 387-392, 1998.
21. Ito M, Oliverio MI, Mannon PJ, Best CF, Maeda N, Smithies O, Coffman TM. Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci USA 92: 3521-3525, 1995.
22. Johnston AP, Baker J, Bellamy LM, McKay BR, De Lisio M, Parise G. Regulation of muscle satellite cell activation and chemotaxis by angiotensin II. PLos One 5: e15212, 2010.
23. Johnston AP, Bellamy LM, Lisio MD, Parise G. Captopril treatment induces hyperplasia but inhibits myonuclear accretion following severe myotrauma in murine skeletal muscle. Am J Physiol Regul Integr Comp Physiol 301: R363-R369, 2011.
24. Jones A, Woods DR. Skeletal muscle RAS and exercise performance. Int J Biochem Cell Biol 35: 855-866, 2003.
25. Kandpal N, Shukla GK, Bhatia N, Agarwal SP, Saha S, Puri VN. Oxidant, vitamin A and angiogenic markers in laryngeal cancer patients. J Laryngol Otol 117: 871-874, 2003.
26. Kaneko K, Ito M, Fumoto T, Fukuhara R, Ishida J, Fukamizu A, Ikeda K. Physiological function of the angiotensin AT1a receptor in bone remodeling. J Bone Miner Res 26: 2959-2966, 2011.
27. Linderman JR, Greene AS. Distribution of angiotensin II receptor expression in the microcirculation of striated muscle. Microcirculation 8: 275-281, 2001.
28. Lundby C, Nordsborg N, Kusuhara K, Kristensen KM, Neufer PD, Pilegaard H. Gene expression in human skeletal muscle: alternative normalization method and effect of repeated biopsies. Eur J Appl Physiol 95: 351-360, 2005.
29. Lynch GS, Schertzer JD, Ryall JG. Therapeutic approaches for muscle wasting disorders. Pharmacol Ther 113: 461-487, 2007.
30. Müller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 1: 221-228, 2006.
31. Murphy KT, Koopman R, Naim T, Leger B, Trieu J, Ibebunjo C, Lynch GS. Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function. FASEB J 24: 4433-4442, 2010.
32. Murphy KT, Lynch GS. Update on emerging drugs for cancer cachexia. Expert Opin Emerg Drugs 14: 619-632, 2009.
33. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 86: 747-803, 2006.
34. Plant DR, Colarossi FE, Lynch GS. Notexin causes greater myotoxic damage and slower functional repair in mouse skeletal muscles than bupivacaine. Muscle Nerve 34: 577-585, 2006.
35. Roig E, Perez-Villa F, Morales M, Jimenez W, Orus J, Heras M, Sanz G. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 21: 53-57, 2000.
36. Russell ST, Sanders PM, Tisdale MJ. Angiotensin II directly inhibits protein synthesis in murine myotubes. Cancer Lett 231: 290-294, 2006.
37. Ryall JG, Schertzer JD, Lynch GS. Attenuation of age-related muscle wasting and weakness in rats after formoterol treatment: therapeutic implications for sarcopenia. J Gerontol A Biol Sci Med Sci 62: 813-823, 2007.
38. Sanders PM, Russell ST, Tisdale MJ. Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Br J Cancer 93: 425-434, 2005.
39. Sano M, Fukuda K, Kodama H, Pan J, Saito M, Matsuzaki J, Takahashi T, Makino S, Kato T, Ogawa S. Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes. J Biol Chem 275: 29717-29723, 2000.
40. Serrano AL, Baeza-Raja B, Perdiguero E, Jardi M, Munoz-Canoves P. Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab 7: 33-44, 2008.
41. Sim J, Reid N. Statistical inference by confidence intervals: Issues of interpretation and utilization. Phys Ther 79: 186-195, 1999.
42. Spurney CF, Sali A, Guerron AD, Iantorno M, Yu Q, Gordish-Dressman H, Rayavarapu S, van der Meulen J, Hoffman EP, Naga-raju K. Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. J Cardiovasc Pharmacol Ther 16: 87-95, 2011.
43. van Esch JH, Gembardt F, Sterner-Kock A, Heringer-Walther S, Le TH, Lassner D, Stijnen T, Coffman TM, Schultheiss HP, Danser AH, Walther T. Cardiac phenotype and angiotensin II levels in AT1a, AT1b, and AT2 receptor single, double, and triple knockouts. Cardiovasc Res 86: 401-409, 2010.
44. Warren GL, Hulderman T, Jensen N, McKinstry M, Mishra M, Luster MI, Simeonova PP. Physiological role of tumor necrosis factor a in traumatic muscle injury. FASEB J 16: 1630-1632, 2002.
45. Webster C, Silberstein L, Hays AP, Blau HM. Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Cell 52: 503- 513, 1988.
46. Wei Y, Sowers JR, Clark SE, Li W, Ferrario CM, Stump CS. Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kB activation via NADPH oxidase. Am J Physiol Endocrinol Metab 294: E345-E351, 2008.
47. Wray DW, Nishiyama SK, Harris RA, Richardson RS. Angiotensin II in the elderly: impact of angiotensin II type 1 receptor sensitivity on peripheral hemodynamics. Hypertension 51: 1611-1616, 2008.
48. Yamamoto T, Nakagawa T, Suzuki H, Ohashi N, Fukasawa H, Fujigaki Y, Kato A, Nakamura Y, Suzuki F, Hishida A. Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J Am Soc Nephrol 18: 1558-1565, 2007.
49. Zhang L, Du J, Hu Z, Han G, Delafontaine P, Garcia G, Mitch WE. IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol 20: 604-612, 2009.
50. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci USA 105: 15896-15901, 2008.